As the industry—and the world—faces unprecedented challenges, your choice of CDMO plays an increasingly important role in the success of your project. New formulations and underserved patient populations demand a level of expertise many development and manufacturing partners simply don’t have. Is your CDMO partner able to adapt to today’s ever-changing world? Giovanni Ortenzi, the leader of Adare Pharma’s global pharmaceutical development and technical services, was recently interviewed about how Adare is uniquely qualified to meet and overcome these new challenges. Adare’s unique mix of expertise, innovation, and capacity makes us the perfect choice to bring your new project to market.
Flexible-Dose Development Strategies for Today's Clinical Landscape - Executive Summary
January 8th 2025This executive summary focuses on dose-flexible manufacturing strategies and their role in drug development. Dose flexibility is increasingly important for early clinical studies, particularly in areas such as pediatric medicines and oncology. However, flexible dosing strategies are often neglected or not prioritized early in development. This presentation will focus on technical strategies that can help anticipate appropriate timing for implementation and how to do so cost effectively while adhering to required timelines.
Molecular Properties of PROTACs and the Relationship to Formulation Design
December 20th 2024Analyzation of a diverse set of PROTAC (Proteolysis Targeting Chimeras – a class of TPDs) structures and their calculated properties, identifying key structure-property trends that contribute to low oral bioavailability.
Clinical Supply Planning in Europe - Balancing Cost, Flexibility and Time
December 19th 2024The packaging and distribution of clinical supplies is a fundamental piece to the overall success of a clinical trial, and advance preparation can help establish a more efficient supply chain. Selecting the best geographical location for those activities, however, depends on the clinical trial protocol, business decisions, and even the investigational medicinal product (IMP) being studied.